MedTrace Logo

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

NCT02186119 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2015-07-14

No results posted yet for this study

Summary

This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.

Conditions

  • Macular Edema

Interventions

DRUG

abicipar pegol

Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.

DRUG

ranibizumab

Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.

OTHER

sham procedure

Sham procedure to the study eye at the visits noted per protocol.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02186119 on ClinicalTrials.gov